Utama › Limfoma Folikular › Washington › Seattle
Kajian klinikal Limfoma Folikular di Seattle, WA
15 kajian untuk Limfoma Folikular sedang mencari peserta di lokasi dalam dan sekitar Seattle (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
Mengambil pesertaFasa 1/2
- Research Site, Seattle
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Mengambil pesertaFasa 1/2
- Fred Hutchinson Cancer Research Center, Seattle
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
Mengambil pesertaFasa 1
- University of Washington - Fred Hutchinson Cancer Center (Seattle Cancer Care Alliance), Seattle
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
Mengambil pesertaFasa 1
- Swedish Cancer Institute (SCI), Seattle
A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
Mengambil pesertaFasa 1/2
- Fred Hutchinson Cancer Research Center, Seattle
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
Mengambil pesertaFasa 3
- Fred Hutch Cancer Center, Seattle
Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma
Mengambil pesertaFasa 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
Mengambil pesertaFasa 1
- Fred Hutchinson Cancer Center, Seattle
Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial
Mengambil pesertaFasa 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Mengambil pesertaFasa 2Sukarelawan sihat dialu-alukan
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Study of SGR-1505 in Mature B-Cell Neoplasms
Mengambil pesertaFasa 1
- Fred Hutchinson Cancer Center, Seattle
A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma
Mengambil pesertaFasa 1/2
- University of Washington-Seattle Cancer Care Alliance, Seattle
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Mengambil pesertaKajian pemerhatian
- Massive Bio SYNERGY-AI site, Seattle
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
Mengambil pesertaFasa 1
- Swedish Cancer Institute, Seattle
Study of the Clinical Impact of Surgical Correction of Tricuspid Insufficiency in Implantable LVAD Patients
Mengambil peserta
- University of Washington Medical Center, Seattle
Kajian Limfoma Folikular di bandar lain
- New York City, NY24 kajian
- Milwaukee, WI19 kajian
- Nashville, TN18 kajian
- Houston, TX18 kajian
- Boston, MA17 kajian
- Baldwin Park, CA16 kajian
- Durham, NC15 kajian
- Columbus, OH13 kajian
- Salt Lake City, UT13 kajian
- San Antonio, TX12 kajian
- Chicago, IL12 kajian
- Philadelphia, PA12 kajian
Kajian lain di Seattle
- Kanser Paru-paru Bukan Sel Kecil53 kajian
- Kanser (semua jenis)49 kajian
- Kanser Prostat42 kajian
- Leukemia Mieloid Akut40 kajian
- Kanser Payudara39 kajian
- Kanser Metastatik39 kajian
- Kanser Kolorektal34 kajian
- Kanser Paru-paru33 kajian
- Kanser Ovari30 kajian
- Mieloma Pelbagai22 kajian
- Sindrom Mielodisplastik21 kajian
- Leukemia Limfoblastik Akut21 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.